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Background
Ipilimumab, a fully human monoclonal antibody (IgG1)
that promote antitumor immunity by blocking CTLA4,
was the first agent which showed a long-term survival
benefit, about the 20% of patients, for the treatment of
metastatic melanoma. The combination of ipilimumab
with other therapies might improve its efficacy.
The term “abscopal effect” refers to a regression of meta-
static lesions distant from the primary site of radiotherapy
(RT). This new phenomenon represent the systemic
response observed in patients who received ipilimumab.
Here we reported the outcomes from patients treated
in the ipilimumab Italian expanded access program
(EAP) who received RT after ipilimumab progression.
Patients and methods
Patients with advanced melanoma after ipilimumab pro-
gression were selected for analysis. Patients, who failed
ipilimumab therapy and for whom no other therapeutic
options were available, were elegible for radiotherapy.
Results
21 out of 95 patients treated with ipilimumab in the Italian
EAP were eligible for the analysis. The median age was of
58 years (range 21-77); The progression free survival (PFS)
from ipilimumab treatment was 4 months (range 3-6),
while the time from the end of treatment with ipilimumab
and RT was of 5 months (range 4-8).
RT was performed on brain in 13 (62%) patients: 8 were
treated with whole-brain RT and 5 patients with stereotac-
tic RT. Other RT treatment included bone, metastatic dis-
tant lymph nodes, sub-cutaneous metastasis, spinal cord
metastatis. The median doses of radiation was of 30 Gy
(range 30-50). A local response to RT was detected in
13 patients (62%) while 8 patients (38%) did not show any
local regression. The abscopal response has been detected
in 11/21 (52%) patients: in details, we observed 9 abscopal
partial response (42,8%), 2 abscopal stable disease (9,6%),
and 10 progression (47,6%). The median of occurrence of
the abscopal response was of 1 month (range 1-4). The
median overall survival (OS) for all the 21 patients was of
13 months (range 6-26). The median OS for patients
with and without abscopal responses was respectively of
22.4 months (range 2,5-50,3) and 8,3 months (range
7,6-9.0). 11 (84,6%) out of 13 patients with local response
showed an abscopal effect.
Conclusions
RT could be a new treatment option after ipilimumab
treatment for potentiate its effect. Local response to RT
might be predictive for the abscopal response and out-
come. Further studies are warranted in this field to better
understand and define the role of RT in combination or
sequencing with ipilimumab treatment.
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